Treatment and Prevention of Osteoporosis during COVID-19 Outbreak: Management and Adherence to Treatment Guidelines

Abstract

A total of 219 countries, areas, or territories have globally witnessed the existence of a novel Coronavirus (COVID-19) pandemic over the last few months, which posed serious threats to human health. The viral incubation period varies from 2 to 14 days. It has been observed that osteoporosis patients are likely to be at high risk of COVID-19 contracting sequelae. Osteoporosis is a chronic condition that reduces bone strength and increases the risk of fracture. Osteoporosis typically requires sustained therapeutic intervention to reduce the risks of further bone loss, structural integrity impairment and incidence of fractures. In the COVID-19 pandemic, diagnosis of chronic osteoporosis conditions should not become an unwanted casualty. Metabolic bone condition may lead to complications in COVID-19 infected patients. Orthopaedic doctors are being redeployed in different hospitals to treat COVID-19 infected patients. Thus, the orthopaedics community needs compulsory training to understand the symptoms of this condition. Orthopaedics surgery and trauma surgery are challenging in a hospital setup with limited availability of hospital staff and operating facilities. Clinicians must respond to the challenges raised by this crisis and consider ways of continuing to help patients with chronic diseases with their substantive morbidity and mortality.